China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its high-concentration hydroxocobalamine. The drug is intended for the treatment of pediatric methylmalonic acidemia (MMA) with elevated homocysteine (cblC type).
Significant Unmet Medical Need
MMA, an autosomal recessive organic acid metabolism disorder, has been included in China’s First List of Rare Diseases. Hydroxocobalamin is the first-line treatment for vitamin B12-responsive MMA and requires long-term use. Currently, there is no hydroxocobalamin approved for this indication either domestically or internationally, highlighting a significant unmet medical need.-Fineline Info & Tech
